PDK1 and cancer: Future studies focusing on the development of more selective PDK1 inhibitors, along with combination therapies, will be necessary to optimize the therapeutic efficacy of PDK1 inhibition.Pan-cancer analysis found that PDK1 is abnormally overexpressed in various types of malignant tumors and is a poor prognostic factor for various types of malignant tumors.